Hi, friends, being AI enthusiast, I'm an MBA, CEO and CPO who loves building products. I share my insights here.) Hi, friends, being AI enthusiast, I'm an MBA, CEO and CPO who loves building products.

NPR's Scott Simon speaks to writer Matt Klein about how to win back our attention in an age of infinite information. UNIDENTIFIED PERSON: (Laughter). SIMON: Oh, I - yeah. Oh, I - my daughter just sent ...

There is a particular kind of uncertainty that clings to every NBA draft pick — the wide-eyed, romantic uncertainty of projection. It is the mystery that animates fanbases, front offices, and entire ...

According to God of Prompt on Twitter, the implementation of verification loops in AI models—where the system recursively checks its answers using different reasoning modes such as backward ...

Anthropic released Cowork on Monday, a new AI agent capability that extends the power of its wildly successful Claude Code tool to non-technical users — and according to company insiders, the team ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Beth Skwarecki is Lifehacker’s Senior Health Editor, and holds certifications as a personal trainer and weightlifting coach. She has been writing about health for over 10 years. Add as a preferred ...

According to @godofprompt, recursive prompting is an AI technique where system outputs are fed back in as inputs to refine solutions through multiple iterations (source: @godofprompt, Dec 16, 2025).

Here’s how pinning a utopian vision for AI on LLMs kicked off the hype cycle that’s causing fears of a bubble today. Each time you’ve heard a borderline outlandish idea of what AI will be capable of, ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect of the process, including human developers using the tools to improve ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...